ArticleCell death & disease2025
Dual effects of the alternative spliced RIG-I isoform PTIR1 on host antiviral defense and immune homeostasis.
Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Efficient pathogen recognition must be tightly regulated to prevent immunopathology. Here, we identify PTIR1, a primate-specific splice variant of DDX58 lacking exon 4 and encoding a truncated RIG-I isoform, as a negative regulator of innate immune signaling. PTIR1 is selectively induced upon viral infection or interferon (IFN) stimulation, and its ectopic expression via adenoviral delivery broadly suppresses inflammatory responses in vivo. Mechanistically, PTIR1 activates the deubiquitinase UCHL5 to limit STAT1 ubiquitination at lysine 525, thereby impairing STAT1 nuclear translocation and dampening type I and type II IFN responses. Accordingly, in a model of autoimmune hepatitis, PTIR1 restricts IFN-γ-driven inflammation, and in a viral infection model, it attenuates type I IFN responses. PTIR1 also modulates RIG-I signaling by interfering with its dimerization, reducing its ubiquitination, and disrupting its interaction with MAVS, thereby limiting RIG-I-mediated antiviral recognition and facilitating viral immune evasion. These findings identify PTIR1 as an inducible post-transcriptional checkpoint that fine-tunes antiviral and inflammatory signaling to preserve tissue integrity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.